(IHI) U.S. Medical Devices - Overview
Etf: Imaging, Prosthetics, Pacemakers, X-Ray, Diagnostics
Dividends
| Dividend Yield | 0.35% |
| Yield on Cost 5y | 0.38% |
| Yield CAGR 5y | -16.50% |
| Payout Consistency | 90.0% |
| Payout Ratio | - |
| Risk 5d forecast | |
|---|---|
| Volatility | 17.1% |
| Relative Tail Risk | 1.28% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.61 |
| Alpha | -22.29 |
| Character TTM | |
|---|---|
| Beta | 0.707 |
| Beta Downside | 0.746 |
| Drawdowns 3y | |
|---|---|
| Max DD | 22.84% |
| CAGR/Max DD | 0.14 |
Description: IHI U.S. Medical Devices January 10, 2026
The iShares U.S. Medical Devices ETF (IHI) aims to replicate the Dow Jones U.S. Select Medical Equipment Index, which tracks U.S. companies that design, manufacture, or distribute non-disposable medical devices such as MRI scanners, prosthetics, pacemakers, and X-ray systems. The fund is classified as a non-diversified ETF within the health category.
Key sector drivers include a projected 5-6% annual growth in U.S. medical device spending, fueled by an aging population and increased outpatient procedures. As of the latest filings, IHI’s top holdings-e.g., Medtronic, Abbott Laboratories, and Boston Scientific-account for roughly 40% of assets, and the fund’s expense ratio sits at 0.43%, modest relative to peers. The non-diversified structure means concentration risk is higher than broadly diversified health ETFs, which should be factored into risk-adjusted return expectations.
For a deeper dive into IHI’s valuation metrics and risk profile, you might explore the analysis tools available on ValueRay.
What is the price of IHI shares?
Over the past week, the price has changed by -2.86%, over one month by -9.38%, over three months by -3.73% and over the past year by -8.55%.
Is IHI a buy, sell or hold?
What are the forecasts/targets for the IHI price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 58.8 | 0.7% |
IHI Fundamental Data Overview February 03, 2026
EBIT TTM = 0.0 USD
EBITDA TTM = 0.0 USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = unknown
Enterprise Value = 3.88b USD (3.88b + (null Debt) - (null CCE))
Interest Coverage Ratio = unknown (Ebit TTM 0.0 / Interest Expense TTM 0.0)
EV/FCF = unknown (FCF TTM 0.0)
FCF Yield = 0.0% (FCF TTM 0.0 / Enterprise Value 3.88b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = unknown (Enterprise Value 3.88b / Total Assets none)
Interest Expense / Debt = unknown (Interest Expense 0.0 / Debt none)
Taxrate = 21.0% (US default 21%)
NOPAT = 0.0 (EBIT 0.0 * (1 - 21.00%))
Current Ratio = unknown (Total Current Assets none / Total Current Liabilities none)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = unknown (Net Debt none / EBITDA 0.0)
Debt / FCF = unknown (Net Debt none / FCF TTM 0.0)
Total Stockholder Equity = 0.0 (from calculated bookValueOfEquity)
RoA = unknown (Net Income 0.0 / Total Assets none)
RoE = unknown (Net Income TTM 0.0 / Total Stockholder Equity 0.0)
RoCE = unknown (EBIT 0.0 / Capital Employed )
RoIC = unknown (NOPAT 0.0, Invested Capital 0.0, EBIT 0.0)
WACC = 8.52% (E(3.88b)/V(3.88b) * Re(8.52%) + (debt-free company))
Discount Rate = 8.52% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow 0.0)